Location Directory

Clinical trials in Pittsburgh, Pennsylvania

This page shows live ClinicalTrials.gov search results for Pittsburgh, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10628

Shown on this page

Current sort

Institutions in Pittsburgh

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

UPMC (University of Pittsburgh)

Live official records

Open in full search

Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cemiplimab, Cisplatin, Computed Tomography, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Salvage Surgery; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 115
States / cities: Tucson, Arizona • Irvine, California • Los Angeles, California + 85 more

Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Interventions: Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration; Drug · Biological · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 445
States / cities: Kingman, Arizona • Jonesboro, Arkansas • Anaheim, California + 346 more

Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
Interventions: Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 5,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1435
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more

Conditions: Cardiac Amyloidosis, AL Amyloidosis, ATTR Amyloidosis
Interventions: [18F]florbetaben; Drug
Lead sponsor: Lantheus Germany GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Kansas City, Kansas • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary Glioblastoma
Interventions: Ipilimumab, Magnetic Resonance Imaging, Nivolumab; Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 413
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 288 more

Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Elastography, Multigated Acquisition Scan, Nivolumab, Sargramostim; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2033
U.S. locations: 763
States / cities: Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 494 more

Conditions: Prosthetic-joint Infection
Interventions: PLG0206, Placebo; Drug
Lead sponsor: Peptilogics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Sarasota, Florida • Tamarac, Florida • Shreveport, Louisiana + 13 more

Conditions: Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
Interventions: ALN-6400; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Orange, California • San Diego, California • San Francisco, California + 7 more

Conditions: Obstructive Sleep Apnea, Cognitive Decline
Interventions: Positive airway pressure, Oral appliance therapy, Positional therapy; Device
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 55 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Tucson, Arizona • New York, New York • Pittsburgh, Pennsylvania

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Echocardiography Test, Electrocardiography, Lumbar Puncture, Mesna, Methotrexate, Multigated Acquisition Scan, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 207
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions: Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 838
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 528 more

Conditions: COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 1,877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 928
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 589 more

Clinical trials in Pittsburgh, Pennsylvania

Filter and sort this location

Institutions in Pittsburgh

Live official records

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCI COVID-19 in Cancer Patients, NCCAPS Study